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Objective: Contrast-enhanced computed tomography (CE-CT) has been commonly used for follow-up imaging after
endovascular aneurysm repair (EVAR), but it is difﬁcult to use on patients with renal insufﬁciency. Superparamagnetic
iron oxide (SPIO) particles, contrast medium for magnetic resonance imaging (MRI) that has been widely used for
detection of the liver tumor, rarely affects renal function. The present study examined SPIO-enhanced dynamic MRI as
a potential alternative to CE-CT for detection of endoleaks after EVAR.
Methods: Institutional review board approval was obtained for this prospective study. Twenty-three consecutive patients
with normal renal function were evaluated using both CE-CT and SPIO-enhanced MRI within 2 weeks after EVAR. The
median interval between the two modalities was 2 days. SPIO-enhanced MRI was performed at 1.5 T with T1-weighted,
SPIO-enhanced dynamic, and postcontrast T1-weighted gradient echo sequences. The CE-CT protocol consisted of triple
scans. Two experienced, blinded observers evaluated all images. Consensus reading of CE-CT and SPIO-MRI was deﬁned
as the reference standard. Interobserver, intraobserver, and intermodality agreement for endoleak detection was assessed
by k statistics.
Results: A total of 11 type II endoleaks originating from either the lumbar or inferior mesenteric artery were detected.
Eight were able to be detected by CE-CT (8/11:73%) and 10 (10/11:91%) by SPIO-enhanced MRI. Interobserver
(k[ 0.91; 95% CI, 0.74-1.00) and intraobserver agreement for MRI (k[ 1.00) were excellent. Intermodality agreement
for endoleak detection was moderate (k [ 0.63; 95% CI, 0.32-0.94; and k [ 0.62; 95% CI, 0.29-0.95 for observers A
and B, respectively).
Conclusions: SPIO-enhanced MRI could represent a useful alternative to CE-CT, as it offers excellent interobserver,
intraobserver agreement, and could detect more endoleaks than CE-CT. (J Vasc Surg 2013;58:66-72.)During the last decade, endovascular aneurysm repair
(EVAR) has become the important modality of treatment
for abdominal aortic aneurysms (AAA). Although previous
multiple randomized controlled trials showed lower 30-day
mortality with EVAR, compared with open AAA repair, the
procedure has also been associated with postoperative
complications such as endoleaks, and a signiﬁcantly higher
rate of secondary interventions.1,2 Because endoleaks may
cause enlargement of aneurysm sac and, thus, increase
the risk of rupture after EVAR, long-term surveillance ofthe Department of Radiologya and Department of Community
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to maintain optimal outcomes.3
Contrast-enhanced computed tomography (CE-CT)
has been commonly used for postoperative surveillance of
EVAR because, in part, of its rapid acquisition time and
high diagnostic value. However, it is also associated with
the cumulative risks of radiation exposure and, most of all,
contrast nephrotoxicity. With increasing reliance on diag-
nostic CT using iodinated intravenous contrast, the inci-
dence of contrast-induced nephropathy is likely to increase.
In a previous article evaluating contrast-induced nephro-
pathy after percutaneous coronary intervention, more severe
renal impairment was found to be correlated with a greater
risk of developing contrast-induced nephropathy,4 so that
the risk is highest in patients with chronic kidney disease
(CKD).
Dynamic contrast-enhanced magnetic resonance im-
aging (MRI) techniques using gadolinium diethylenetri-
amine penta-acetic acid (Gd-DTPA) as a contrast agent
have been shown to be very sensitive for depicting small
endoleaks5 and can have additional value for their classiﬁca-
tion.6 However, the association between nephrogenic
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been reported in patients with CKD.7,8 Contrast-enhanced
ultrasound (CE-US) has also been shown to be sensitive
for detecting endoleaks and to allow for better classiﬁcation
of endoleaks compared with CE-CT.9 However, diagnostic
accuracy of CE-US depends largely on operator skill, and
scan and study qualities are generally poor in obese
patients.
Superparamagnetic iron oxide (SPIO) particles were
originally developed as contrast medium for MRI of the
liver, where they are administered to improve tumor detec-
tion with T2-weighted imaging (T2WI). The SPIO parti-
cles improve contrast by being taken up by the Kupffer
cells of normal liver tissues but not by metastases or
primary liver tumors. Intravenously injected SPIO particles
also shorten the T1 relaxation time, and thus, vascularized
structures show signal enhancement on T1-weighted
imaging (T1WI),10,11 so SPIO-enhanced MRI may have
the potential to detect endoleaks. SPIO is different from
Gd-DTPA. SPIO is metabolized as iron, the rate of urinary
excretion is less than 0.5%, and it is extremely rare that
SPIO complicates renal function.12,13 If SPIO-enhanced
MRI is proven to be effective for endoleak detection, it
should be useful for monitoring patients with CKD after
EVAR. The purpose of this study was to examine SPIO-
enhanced MRI as a potential alternative to CE-CT for
detection of endoleaks after EVAR.
METHODS
Patients. Twenty-three consecutive patients who
underwent implantation of nitinol aortic stent grafts for
AAA were recruited to this prospective study. No patients
had contraindications of use of SPIO (ie, history of iron
allergy or hemochromatosis), and administration of SPIO
could be performed in every patient. The median patient
age was 79 (range, 71-83) years (male, n ¼ 20; female,
n ¼ 3). The median body weight was 61 kg (range, 45-
71 kg). The median sac diameter was 48.5 mm (range,
44.5-53.7 mm). Excluder stent grafts (Gore Medical,
Newark, Del) were implanted in 10 patients and Endurant
stent grafts (Medtronic, Fridley, Minn) were implanted in
13. CE-CT and SPIO-enhanced MRI were performed
for endoleak detection within 2 weeks after EVAR. The
time period between CE-CT and SPIO-enhanced MRA
was not more than 1 week. Written informed consent was
obtained from all patients. The institutional review board
approved this prospective study.
CE-CT. All examinations were performed with a dual-
source 64 slice CT scanner (Somatom Deﬁnition; Siemens
Medical Solutions, Erlangen, Germany). A triple-phase
CT protocol consisting of a nonenhanced, arterial and
a delayed venous phase encompassing the abdomen and
pelvis from the level of the cardiac apex to the femoral head
was performed. After standard nonenhanced data acquisi-
tion, arterial phase scanning was performed using a bolus-
tracking technique. A total of 100-150 mL of nonionic
iodinated contrast medium was administered at a ﬂow rate
of 4 mL/s. All injections were followed by a chaser bolus of30 mL of saline solution. The arterial phase data acquisition
was initiated 6 seconds after the attenuation reached
a predeﬁned threshold of 120 HU. This delay allowed the
patient to receive breathing instructions and facilitated
maximal aortic enhancement. Delayed phase dual-energy
CT scanning was performed with a standard delay of
70 seconds after the beginning of the contrast material
injection.
SPIO-enhanced MRI. All scans were performed at
1.5 T (Siemens Medical Solutions). Before injection of
SPIO, native turbo fast low angle shot magnetic resonance
imaging (FLASH) and volumetric interpolated breath-
hold examination (VIBE) sequences were performed
under breath-hold conditions (Table I). Resovist (Fujiﬁlm
RI Pharma Co, Tokyo, Japan), a bolus injectable SPIO,
was used as the contrast medium. Depending on patient
weight, a dose of 0.6-1.4 mL (0.016 mL/kg body weight)
of Resovist was injected at 1.0 mL/s followed by a 20 mL
saline ﬂush administered at the same rate using an elec-
tronic power injector (Spectris Solaris; Medrad, Warren-
dale, Pa). After injection, the ﬂuoroscopic triggering
technique using two-dimensional sagittal gradient refo-
cused images (CareBolus technique) was obtained rapidly
through the thoracic aorta. When the contrast bolus
arrived at the descending aorta, the turbo FLASH
sequence was started for the vascular phase. The VIBE
sequence was started 2 minutes after injection. These series
were also evaluated after subtraction processing. Subtrac-
tion imaging is a technique whereby an unenhanced T1-
weighted sequence is digitally subtracted from the
identical sequence performed after SPIO administration.
By performing this operation, the native T1 signal is
removed and any signal remaining on the subtracted
images is due solely to enhancement (ie, endoleaks). MR
angiography (MRA) images were also obtained by
maximal intensity projection processing on subtraction
images.
Image analysis. Analysis of CE-CT and SPIO-
enhanced MRI was performed by two independent radi-
ologists (S.I. and N.M., with 9 and 16 years of experience
in vascular imaging, respectively) who were blinded to
previous angiographic results. Both readers independently
reviewed all images and evaluated the presence and types of
endoleaks. The order in which the different reading
sessions were performed was selected randomly by another
radiologist (T.T.) who was not involved in the reading
sessions. The classiﬁcation of endoleaks was performed
according to the criteria proposed by White et al14: type I,
II, III, IV, and unknown (meaning the exact site of inﬂow
could not be identiﬁed). One observer (S.I.) evaluated CE-
CT and SPIO-enhanced MRI twice for intraobserver
comparison with an interval between the ﬁrst and second
evaluations of more than 1 month. During the second
evaluation, the observer was blinded to the results of the
ﬁrst evaluation. In addition to the endoleak evaluation,
patencies of the endografts and renal arteries were also
evaluated by a single observer (S.I.) referring to the MRA.
Dynamic scans were considered technically unsuccessful if
Table II. Summary of the type II endoleaks detected by
CT and/or MRI
Patient
number Age Sex Endograft CT MRI
Endoleak
origin
1 92 M Excluder þ þ LA
2 74 M Endurant þ þ LA
3 76 F Excluder þ þ LA
4 78 F Endurant þ þ LA
5 83 M Endurant þ þ IMA
6 71 M Endurant þ þ IMA
7 81 M Endurant þ þ IMA
8 65 M Excluder þ  LA
9 86 F Excluder  þ IMA
10 59 M Excluder  þ IMA
11 72 M Endurant  þ LA
CT, Computed tomography; F, female; IMA, inferior mesenteric artery; LA,
lumbar artery, M, male; MRI, magnetic resonance imaging; þ, detected; ,
undetected.
Table I. MRI scan parameter
Parameter Turbo FLASH VIBE
TR, milliseconds 2.51 2.95
TE, milliseconds 0.88 1.1
FA,  25 10
Slice thickness, mm 1.5 3
FOV, mm 350 350
Matrix 147  256 176  256
Slice per slab 128 60
Scan time, seconds 16 25
FA, Flip angle; FLASH, fast low angle shot magnetic resonance imaging;
FOV, ﬁeld of view; MRI, magnetic resonance imaging; TE, echo time; TR,
repetition time; VIBE, volumetric interpolated breath-hold examination.
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motion, fold-over artifacts, or misregistration artifacts.
Statistical analysis. Categorical variables are expressed
as frequencies or percentages. Interobserver, intraobserver,
and intermodality agreements for endoleak detection were
assessed by k statistics as follows: k values of 0.00-0.40
were considered to indicate poor agreement; 0.41-0.75,
fair to good agreement; and 0.76-1.00, excellent agree-
ment.15 When disagreements were encountered between
the two readers about the existence of endoleaks, a discus-
sion was held until consensus could be reached. Consensus
reading of MRI and multidetector computed tomography
studies was deﬁned as reference standard, similar to pre-
vious studies.5,16 All statistical tests were performed using
SPSS v. 20 software (IBM, New York, NY).
RESULTS
The median interval between CE-CT and SPIO-
enhanced MRI was 2 days (0-7 days). All patients
completed the protocol, and no adverse events were
recorded. All MRI images could be evaluated without
signiﬁcant motion or misregistration artifacts, and there
were no unsuccessful scans.
At consensus reading, endoleaks were detected in 11
patients in total by CT and/or MRI (11/23:47%). All
endoleaks were type II and originated from either the
lumbar (n ¼ 6) or inferior mesenteric artery (n ¼ 5).
CE-CT was able to detect eight of the endoleaks
(8/11:73%) and SPIO-enhanced MRI was able to detect
10 (10/11:91%) (Table II; Fig 1). All 10 endoleaks
detected by SPIO-enhanced MRI were detected by
subtraction dynamic images, whereas three endoleaks
were not detected by nonsubtraction conventional
dynamic images. One type II endoleak from the lumbar
artery and two type II endoleaks from the inferior mesen-
teric artery visualized by SPIO-enhanced MRI could not
be detected by CE-CT (Fig 2). These endoleaks broadened
with time on dynamic scan and connected with the lumbar
artery or the inferior mesenteric artery, which were thought
to be origin of the endoleaks. On the other hand, one type
II endoleak from the lumbar artery visualized by CE-CT
could not be detected by SPIO-enhanced MRI. A
consensus reading was required for one patient in bothCE-CT and SPIO-enhanced MRI. Misregistration artifacts
were seen in three cases, although these artifacts did not
affect the image interpretations. Interobserver (k ¼ 0.91;
95% CI, 0.74-1.00) and intraobserver agreement for
MRI (k ¼ 1.00) were excellent. Intermodality agreement
for endoleak detection was moderate (k ¼ 0.63; 95% CI,
0.32-0.94; and k ¼ 0.62; 95% CI, 0.29-0.95 for observers
A and B, respectively).
Graft and renal artery patency could be evaluated in all
patients (Fig 3). All renal arteries were patent; however, in
one patient, after implantation of the Excluder endograft,
stenosis of the ipsilateral limb because of compression by
the contralateral limb was clearly detected by MRA
(Fig 4). In this patient, additional kissing balloon dilation
was performed as a secondary intervention.
DISCUSSION
Endoleaks are frequent problems after EVAR. Previous
CE-CT-based studies have shown that 20%-40% of patients
had an initial endoleak, many of which were type II.17 In
the present study, type II endoleaks were able to be
detected in eight patients by CE-CT and in 10 patients
by SPIO-enhanced MRI. Sensitivity of CE-CT for endo-
leak detection has been reported to be 82%-83%.9,18 On
the other hand, contrast-enhanced MRI using Gd-DTPA
has been shown to be signiﬁcantly more sensitive for endo-
leak detection than CE-CT because of the high sensitivity,
intrinsic three dimensionality, and excellent soft tissue
contrast.5
Resovist, the bolus injectable SPIO, shortens both T1
and T2 relaxation times, but the shortening of T2 is
much greater than that of T1.19 The positive T1 contrast
effect is less pronounced compared with Gd-DTPA.20-22
Unlike Gd-DTPA, however, Resovist is characterized by
a biexponential blood half-life of 3.9-5.8 minutes and
a blood pool effect.22 Therefore, it was hypothesized that
Resovist may have the potential to allow evaluation of
endoleak detection after EVAR. The present study showed
Fig 1. a, Contrast-enhanced computed tomography (CE-CT) demonstrates type II endoleak from lumbar artery.
b, Superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance imaging (MRI) also clearly demonstrates type
II endoleak from lumbar artery. c, CE-CT in another patient demonstrates minimal type II endoleak from lumbar
artery. d, SPIO-enhanced MRI also shows type II endoleak from lumbar artery.
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MRI were excellent and the intramodality agreement
between CE-CT and SPIO-enhanced MRI was fair to
good. Intermodality agreement was lower than the intra-
observer and interobserver agreement because the number
of endoleaks detected by SPIO-MRI was greater than by
CE-CT. Therefore, SPIO-enhanced MRI might be a useful
alternative to CE-CT, and the ability to detect endoleaks
with SPIO-enhanced MRI could be higher than in CE-CT.
Subtraction dynamic sequences under breathholding
were key images for detecting endoleaks. Among the 10
endoleaks detected by subtraction dynamic sequences,
only seven were detected by conventional dynamic scans.
Possible reasons for this include the fact that an aneurysm
sac contains fresh thrombus that shows as high intensity
signal on T1WI. The minimally enhanced areas, such as
type II endoleaks among the T1WI high signal clots, couldbe easily overlooked. Removing any pre-existing signal in
T1WI unenhanced images causes contrast enhancement
within an aneurysmal sac to become more conspicuous
on subtracted sequences.
Misregistration artifacts are a drawback of subtraction
processing.23 An imperative technical principle of subtrac-
tion imaging is to keep all parameters constant on the
unenhanced and contrast-enhanced images and to ensure
that the patient’s position remains unchanged. Misregistra-
tion artifacts were identiﬁed in three cases in this study,
probably because of patient movement. However, these
artifacts did not affect image interpretation.
This study also demonstrated that SPIO-enhanced
MRI could be used for MRA, and clearly showed patency
of the graft or renal arteries. Stenosis of a grafted limb was
clearly demonstrated by MRA in one patient. In addition
to endoleak evaluation, post-EVAR analysis such as renal
Fig 2. a, Plain computed tomography (CT). b, Contrast-enhanced computed tomography (CE-CT), arterial phase.
c, CE-CT, equilibrium phase. d, Magnetic resonance imaging (MRI) dynamic series. e, Equilibrium phase, 2 minutes
after superparamagnetic iron oxide (SPIO) injection. CT images shows (a-c) no enhanced lesion in the aneurismal sac.
Arrowheads indicate calciﬁcations of the arterial wall. MRI subtraction dynamic image (d and e) shows enhanced lesion
in the left side of the graft and the enhanced area broadened on equilibrium phase.
Fig 3. a, Completion angiogram after endovascular aneurysm repair (EVAR) shows bilateral renal arteries (arrows) are
patent. b, Superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance angiography (MRA) clearly shows
patent bilateral renal arteries (arrows) same as completion angiogram.
JOURNAL OF VASCULAR SURGERY
70 Ichihashi et al July 2013artery coverage or graft kinking/stenosis might be able to
be evaluated by SPIO-enhanced MRI.
Contraindication of the use of SPIO is the presence of
iron allergy or hemochromatosis. On the other hand,
anaphylaxis, headache, back pain, and nausea have been
listed as side effects of Resovist; however, this frequencyhas been reported to be less than 1%. SPIO particles are
mostly taken up by the reticuloendothelial system in the
liver and spleen and metabolized as iron. There is no risk
of toxicity if SPIO is used within normal dose. No acute
or subacute toxic effects were detected by histologic or
serologic studies in rats or beagle dogs who received a total
Fig 4. a, Plain computed tomography (CT) axial image. b, Superparamagnetic iron oxide (SPIO)-enhanced dynamic
magnetic resonance imaging (MRI) axial image with subtraction. c,Magnetic resonance angiography (MRA). a and b,
Arrowheads show compression of the left iliac limb. SPIO-enhanced MRA (c) clearly showed the stenosis of the left iliac
limb (arrow).
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MR imaging of the liver.12
The most signiﬁcant advantage of using SPIO-
enhanced MRI is that SPIO is free of adverse effects on
renal function and can be used in patients with CKD.
CE-US may be available in CKD patients; however, its
diagnostic accuracy largely depends on operator skill, and
its reproducibility is relatively low compared with SPIO-
enhanced MRI, especially in obese patients. Furthermore,
it is noteworthy that SPIO-enhanced MRI may visualize
the thoracic cavity and, thus, be useful for post-thoracic
endovascular aortic repair surveillance, although further
investigation of post-thoracic endovascular aortic repair
patients is necessary.
The present study has several limitations. First, this is
a preliminary report, and the study population was small.
Second, we used consensus reading of both observers eval-
uating CT and MRI data as the standard of reference
similar to previous studies,5,16 and we did not perform
digital subtraction angiography or CE-US to conﬁrm three
endoleaks that were detected only by MRI; however, these
endoleaks broadened with time on dynamic scan and con-
nected with the lumbar artery or the inferior mesenteric
artery, which were thought to be the origin of the endo-
leaks. In addition, a consensus reading was required for
only one patient in SPIO-enhanced MRI. This is why it
could be quite unlikely that these were false positives.
Third, because ferromagnetic stainless steel stents might
carry the risk of migration and extensive artifacts, only
MRI-compatible nitinol stent grafts were included in this
study. Fourth, in this study, SPIO-enhanced MRI was con-
ducted only in patients without renal dysfunction. Fifth,
cost of SPIO-MRI might well be more expensive than
CE-CT. Finally, although ultrasmall SPIO with a longer
blood half-life may be more suitable for endoleak detec-
tion,24,25 ultrasmall SPIO was not available in our country
during the study period.In conclusion, SPIO-enhanced MRI may be a useful
alternative to CE-CT for detection of endoleaks after
EVAR. Large-scale studies including patients with renal
impairment are mandatory to obtain conclusive evidence
in support of the use of SPIO-enhanced MRI for detection
of endoleaks after EVAR.
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